Buy Recombinant Monkeypox virus/MPXV A35R Protein, C-His for ELISA

Catalog No.

EVV13101

Expression system

Mammalian Cells

Species

Monkeypox virus (MPXV)

Protein length

Val57-Thr181

Predicted molecular weight

16.65 kDa

Nature

Recombinant

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 5% Trehalose, 5% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

A35R, Bifunctional EEV membrane phosphoglycoprotein, Bifunctional EEV membrane phosphoglycoprotein/associates with A36R, Bifunctional EEV membrane protein, EEV membrane phosphoglycoprotein, EEV membrane phosphoglycoprotein C-type,EEV membrane phosphoglycoprotein, C-type lectin-like domain, MPXV-COP-139, MPXV-SL-139, MPXV-WRAIR139

Note

For research use only.

SDS-PAGE

SDS PAGE for Recombinant Monkeypox virus/MPXV A35R Protein
Bioactivity

Anti-MPXV A35R Antibody (SAA0287) binds with A35R protein
Bioactivity

Binding of the A35R-Fc chimeric protein to antibody 40886-T62 (A) or RVV13101 (B) by enzyme-linked immunosorbent assay (ELISA). Ctrl represented negative control (BSA). The commercial A35R protein is the positive control.
Data sourced from citation (PMID: 39861905)
Bioactivity

Quantitative measurement of antigen‐specific binding antibody titers against the viral protein A35R or M1R in murine serum was performed via enzyme‐linked immunosorbent assay (ELISA).
Data sourced from citation (PMID: 41583908)
Bioactivity

Immunization with the chimeric A35R-Fc enhances the induction of MPXV-neutralizing antibodies in mice. (A). Schematic diagram of immunization and sample collection. BALB/c mice (n = 5/group) were intramuscularly immunized twice with 5 μg of A35R or 15 μg of the Fc-fused A35R, formulated with CPG1018 or alum adjuvant with a 14-day interval. A group of mice was injected with empty-LNP as a control group. After immunization, the serum was collected at point times. Specific antibodies against A35R in the serum were tested by an enzyme-linked immunosorbent assay at day 14 (B), day 28 (C), and day 42 (D).
Data sourced from citation (PMID: 39861905)
Bioactivity

Figure S16 Long-term immunogenicity and vaccine efficacy of MV2 in 280 day post-vaccination protection. A.Binding antibody titers.
Data sourced from citation (PMID: 41583908)
Surface Plasmon Resonance

Characterization of the affinity of A35R, A35R-Fc, or A35R-Fc (CHO) with antibody 40886-T62 (C-E) or RVV13101 (F-H) using SPR. The actual responses (colored lines) are shown. The equilibrium dissociation constant KD was calculated as kd/ka. The EC50 was calculated by fitting the OD450 values from serially diluted antibody 40886-T62 or RVV13101 to a sigmoidal dose-response curve.
Data sourced from citation (PMID: 39861905)
ELISPot

The vaccine group exhibited robust cellular immune responses. (A) Detection of IFN‐γ secretion levels using A35R protein as a stimulus. (B) Detection of IL‐2 secretion levels using A35R protein as a stimulus.
Data sourced from citation (PMID: 41583908)
Surface Plasmon Resonance

To further evaluate the reactivity of the chimeric protein and its potential for detecting MPXV infection, we assessed the binding activity of A35R-Fc with human plasma samples obtained from patients recovered from MPXV-infected or co-infected with MPXV and HIV, using surface plasmon resonance.
Data sourced from citation (PMID: 39861905)
ELISPot

The vaccine group exhibited robust cellular immune responses. (E) Detection of IFN‐γ secretion levels using A35R and M1R protein as a stimulus. (F) Detection of IL‐2 secretion levels using A35R and M1R proteins as a stimulus.
Data sourced from citation (PMID: 41583908)
Bioactivity

Binding curves of A35R-FC with the human plasma samples determined by a biolayer interferometry assay. Data show the change in RU signal over time at a certain dilution (serum dilution).These tests represent three replicates.
Data sourced from citation (PMID: 39861905)
ELISPot

Figure S16 Long-term immunogenicity and vaccine efficacy of MV2 in 280 day post-vaccination protection. C.D. The number of IFN-γ and IL-2 spots produced by the spleen of mice stimulated by A35R and M1R.
Data sourced from citation (PMID: 41583908)
ELISPot

Figure S7 Spot images from the Elispot IFN-γ assay using different proteins as stimuli. A.Spot images from the ELISpot IFN-γ assay using A35R protein as the stimulus. B.Spot images from the ELISpot IFN-γ assay using M1R protein as the stimulus. C.Spot images from the ELISpot IFN-γ assay using A35R and M1R proteins as the stimulus.
Data sourced from citation (PMID: 41583908)
ELISPot

Figure S8 Spot images from the Elispot IL-2 assay using different proteins as stimuli. A.Spot images from the ELISpot IL-2 assay using A35R protein as the stimulus B.Spot images from the ELISpot IL-2 assay using M1R protein as the stimulus C.Spot images from the ELISpot IL-2 assay using A35R and M1R proteins as the stimulus
Data sourced from citation (PMID: 41583908)

An mRNA Vaccine Based on Antigens From Conserved Regions of Monkeypox Virus A35R and M1R With a Dimer-Like Conformation Confers Protection Against Both Monkeypox Virus and Vaccinia Virus Infections in Mice. [EVV13101]

Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine., PMID:18482742

Monkeypox infection elicits strong antibody and B cell response against A35R and H3L antigens., PMID:36687315

Rational development of multicomponent mRNA vaccine candidates against mpox., PMID:36947428

Development of multi-epitope vaccines against the monkeypox virus based on envelope proteins using immunoinformatics approaches., PMID:36993967

Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus., PMID:37117161

Design peptide and multi-epitope protein vaccine candidates against monkeypox virus using reverse vaccinology approach: an in-silico study., PMID:37154825

Three neutralizing mAbs induced by MPXV A29L protein recognizing different epitopes act synergistically against orthopoxvirus., PMID:37288876

Multi-valent mRNA vaccines against monkeypox enveloped or mature viron surface antigens demonstrate robust immune response and neutralizing activity., PMID:37300753

Immunogenic proteins and potential delivery platforms for mpox virus vaccine development: A rapid review., PMID:37353117

Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice., PMID:37429529

Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge., PMID:37435062

Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study., PMID:37475115

Multi-Body Biomarker Entrapment System: An All-Encompassing Tool for Ultrasensitive Disease Diagnosis and Epidemic Screening., PMID:37486783

Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus., PMID:37709783

mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge., PMID:37739969

Cross-reactive antibody response to Monkeypox virus surface proteins in a small proportion of individuals with and without Chinese smallpox vaccination history., PMID:37784185

Evaluation and comparison of immune responses induced by two Mpox mRNA vaccine candidates in mice., PMID:37800627

Immunoinformatic Approach for Rational Identification of Immunogenic Peptides Against Host Entry and/or Exit Mpox Proteins and Potential Multiepitope Vaccine Construction., PMID:37804521

Screening, Expression and Identification of Nanobody Against Monkeypox Virus A35R., PMID:38076734

In silico development of a novel anti-mutation, multi-epitope mRNA vaccine against MPXV variants of emerging lineage and sub-lineages by using immunoinformatics approaches., PMID:38450722

Levels of antibodies against the monkeypox virus compared by HIV status and historical smallpox vaccinations: a serological study., PMID:38767199

Polyvalent mpox mRNA vaccines elicit robust immune responses and confer potent protection against vaccinia virus., PMID:38787725

Analysis of binding and authentic virus-neutralizing activities of immune sera induced by various monkeypox virus antigens., PMID:38829493

Monkeypox virus protein H3L induces injuries in human and mouse., PMID:39168969

Rational design and computational evaluation of a multi-epitope vaccine for monkeypox virus: Insights into binding stability and immunological memory., PMID:39247273

Single-chain A35R-M1R-B6R trivalent mRNA vaccines protect mice against both mpox virus and vaccinia virus., PMID:39423738

A penta-component mpox mRNA vaccine induces protective immunity in nonhuman primates., PMID:39639037

Long-Lasting Protection and Dose Optimization of MPXV Polyvalent Mpox mRNA Vaccines Against Lethal Vaccinia Virus Challenge in Mice., PMID:39726255

Chemical cross-linking facilitates antigen uptake and presentation and provides improved protection from Mpox with a dual-antigen subunit vaccine., PMID:39781294

Enhanced Immunogenicity and Affinity with A35R-Fc-Based Chimeric Protein Compared to MPXV A35R Protein., PMID:39861905

Immunogenicity of monkeypox virus surface proteins and cross-reactive antibody responses in vaccinated and infected individuals: implications for vaccine and therapeutic development., PMID:39994775

Rational mpox vaccine design: immunogenicity and protective effect of individual and multicomponent proteins in mice., PMID:40105863

A Pathogen-Mimicking Monkeypox Virus Nanovaccine Inspired by Assembly of Viral Antigens with β-Glucan and Dendrimer., PMID:40366370

Enhanced Immunogenicity and Affinity with A35R-Fc-Based Chimeric Protein Compared to MPXV A35R Protein. [EVV13101]

Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus. PMID: 37117161

Monkeypox infection elicits strong antibody and B cell response against A35R and H3L antigens. PMID: 36687315

Development of multi-epitope vaccines against the monkeypox virus based on envelope proteins using immunoinformatics approaches. PMID: 36993967

Rational development of multicomponent mRNA vaccine candidates against mpox. PMID: 36947428

Three neutralizing mAbs induced by MPXV A29L protein recognizing different epitopes act synergistically against orthopoxvirus. PMID: 37288876

Document Download

Recombinant Monkeypox virus/MPXV A35R Protein, C-His.pdf

Recombinant Monkeypox virus/MPXV A35R Protein, C-His